Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clemizole hydrochloride adjunctive therapy in Lennox-Gastaut syndrome
2025-522552-20-00Phase 3Authorised
- Sponsor
- Epygenix Therapeutics
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in Lennox-Gastaut syndrome (LGS) comparing Clemizole hydrochloride adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Percent change in CMMS-28 from baseline through end of double-blind period. Planned start May 2026; status: authorised.
02
Drugs
clemizole
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on 2025-522552-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522552-20-00.